Organogenesis Holdings Inc. Class A Common Stock (ORGO)

FairStock Score: 76/100 — HIGH CONVICTION

Key Financials

Strengths

• Conservative balance sheet with debt-to-equity of just 0.19, providing financial flexibility
• Revenue growth of 77.7% demonstrates strong top-line momentum
• FairStock composite score of 76/100 places it in the top tier across value, quality, and momentum factors

AI Analysis

Organogenesis Holdings Inc. Class A Common Stock is a micro-cap healthcare company valued at $302 million. The business generates $564 million in annual revenue with a 5.6% net margin. From a quality standpoint, Organogenesis shows solid Piotroski F-Score of 6/9 and Altman Z-Score of 2.4 in the grey zone. On valuation, the stock is reasonably priced at 15.5x earnings, with offers a 31% margin of safety vs Graham Number of $3. Growth dynamics show revenue growing at 77.7% and profit growth of 469.5%. Our composite FairStock Score of 76/100 reflects strong fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

Organogenesis's 78% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. Operational leverage in the business model means incremental revenue growth could disproportionately boost bottom-line profitability.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer